Advertisement
Canada markets closed
  • S&P/TSX

    21,552.35
    +188.74 (+0.88%)
     
  • S&P 500

    5,137.08
    +40.81 (+0.80%)
     
  • DOW

    39,087.38
    +90.99 (+0.23%)
     
  • CAD/USD

    0.7376
    +0.0011 (+0.15%)
     
  • CRUDE OIL

    79.81
    +1.55 (+1.98%)
     
  • Bitcoin CAD

    84,395.58
    -443.57 (-0.52%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,091.60
    +36.90 (+1.80%)
     
  • RUSSELL 2000

    2,076.39
    +21.55 (+1.05%)
     
  • 10-Yr Bond

    4.1800
    -0.0720 (-1.69%)
     
  • NASDAQ

    16,274.94
    +183.02 (+1.14%)
     
  • VOLATILITY

    13.11
    -0.29 (-2.16%)
     
  • FTSE

    7,682.50
    +52.48 (+0.69%)
     
  • NIKKEI 225

    39,910.82
    +744.63 (+1.90%)
     
  • CAD/EUR

    0.6802
    -0.0012 (-0.18%)
     

Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

Vir Biotechnology, Inc.
Vir Biotechnology, Inc.

SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectious diseases at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, at 6:10 a.m. PT / 9:10 a.m. ET.

A live webcast of the panel can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.

CONTACT: Contacts: Carly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1-314-368-5189